---
title: "RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286559865.md"
description: "RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI) with a price target of $16.00, while the shares closed at $8.90. Abrahams, a 5-star analyst, has an average return of 11.0% and a 53.80% success rate. The analyst consensus for Karyopharm is Strong Buy, with a price target consensus of $17.60, indicating a 97.75% upside."
datetime: "2026-05-15T11:48:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286559865.md)
  - [en](https://longbridge.com/en/news/286559865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286559865.md)
---

# RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics yesterday and set a price target of $16.00. The company’s shares closed yesterday at $8.90.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Abrahams is a 5-star analyst with an average return of 11.0% and a 53.80% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, ACADIA Pharmaceuticals, and BioCryst.

Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.60, representing a 97.75% upside. In a report released on May 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.

### Related Stocks

- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [Karyopharm (KPTI) Leans on SENTRY in Pivotal Call](https://longbridge.com/en/news/287005767.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)